Objectives. The aim was to describe the clinical characteristics and epidemiology of hypocomplementaemic urticarial vasculitis (HUV; anti-C1q vasculitis) in two geographically defined areas of Sweden.
Introduction
Hypocomplementaemic urticarial vasculitis (HUV)-also named anti-C1q vasculitis in the 2012 revised international Chapel Hill Consensus Conference (CHCC) nomenclature of vasculitides [1] -has been recognized as a specific autoimmune disorder involving 56 months of urticaria with hypocomplementaemia in the presence of systemic manifestations, such as arthritis/arthralgia, glomerulonephritis, uveitis or recurrent abdominal pain [2] . In addition, pulmonary involvement with chronic obstructive pulmonary disease (COPD) is frequently found and constitutes a leading cause of morbidity and mortality [3] . Skin biopsy is essential in the diagnosis of HUV, and the presence of antibodies against complement (C) protein 1q (anti-C1q) has a high sensitivity for this condition [4, 5] . Other typical laboratory findings include low levels of classical complement pathway components (at least one of C1q, C3 and C4) and/or reduced classical complement function in plasma. The histopathology of characteristic urticarial lesions reveals a vasculitis affecting small blood vessels (i.e. capillaries, venules and arterioles), often with leucocytoclasia and perivascular infiltrates composed of neutrophils. The detection of classical complement components with IF microscopy in tissues further strengthens the diagnosis of HUV [6] .
The present knowledge of epidemiology, disease outcome, prognosis and clinical features of HUV is limited. In 2015, Jachiet et al. [7] presented the hitherto largest study from a French nationwide retrospective cohort including 57 cases with data on clinical and laboratory findings and on therapeutic management. However, there are currently no available figures on the prevalence and incidence of this condition. Thus, the objectives of this study were to describe the epidemiology and clinical characteristics of HUV (anti-C1q vasculitis) in two geographically defined populations of Sweden during a 16-year period.
Methods

Study areas and population
Swedish health care is public, tax funded and offers universal access. This study was carried out in two separate geographical areas of Sweden ( Fig. 1 ): Skå ne, the southernmost county of Sweden (study area A), and the county of Ö stergö tland located 400 km northeast of Skå ne (study area B). The total population of the two study areas was 1 284 022 inhabitants in the year 2000 and 1 474 105 inhabitants in December 2015.
Study area A consists of three health-care districts, with a mean population of 950 560 inhabitants during the study period. There are 22 municipalities in the area with Malmö as the largest city. The area is served by four hospitals, all public, with Skå ne University Hospital in Lund and Malmö as a tertiary referral centre offering high-specialized health-care services. Study area B had a mean population of 428 503 inhabitants during the study period and consists of the entire county of Ö stergö tland, including 13 municipalities. The University Hospital in Linkö ping is a tertiary referral centre serving the two other regional public hospitals. The age and sex distributions were similar in both study areas: 014 years 18%; 1554 years 54%; and 555 years 28%, and the female proportion was 50% [8] .
Case identification, ascertainment of diagnosis and inclusion criteria Patients were retrieved from two main registries including both clinical and laboratory databases. All new cases with a diagnosis of HUV during the years 200015 were identified from the registries at the Departments of Rheumatology, Skå ne University Hospital and Linkö ping University Hospital. The second source was the registry at the Department of Clinical Immunology, Skå ne University Hospital in Lund.
Since the early 1980s, all C1q and anti-C1q antibody analyses for both study areas have been carried out at the Department of Clinical Immunology in Lund. Thus, all samples that tested anti-C1q antibody positive for analyses during the years 200015 were reviewed. All case records of patients identified by any of the two retrieval sources were reviewed to ascertain a diagnosis of HUV according to the study criteria. Patients who had a clinical diagnosis of SLE were excluded from the study. Only cases meeting the following criteria were included in this study: a positive anti-C1q antibody test by ELISA; residing within the study areas at the time of HUV diagnosis; and a diagnosis of HUV based on either the CHCC definition [1] and/or typical urticarial skin lesions combined with low levels of classical complement proteins in plasma, plus at least two of the following manifestations: dermal venulitis, arthritis, glomerulonephritis, episcleritis or uveitis, recurrent abdominal pain and anti-C1q antibodies [3] .
Data collection
Demographics, clinical and laboratory data and pathology reports were obtained retrospectively by review of case records. The following data were collected: sex, age at diagnosis, age at disease onset (i.e. first symptoms attributed to HUV), organ involvement at diagnosis and at follow-up, and relevant laboratory data, including autoantibodies and complement consumption. In addition, data on smoking habits were obtained. The patients were stratified into two main groups according to their smoking habits: ever-smokers (active and former smokers) and never-smokers (patients who had never smoked continuously). Data on the outcome in terms of the patient's survival and renal outcome were registered, as either estimated glomerular filtration rate (eGFR) at the last follow-up or the occurrence of end-stage renal disease (ESRD). The eGFR was calculated using the modification of diet in renal disease equation [9] .
Analysis of anti-C1q antibodies
Anti-C1q antibodies were analysed by ELISA and by western blot. For samples obtained between 2000 and August 2011, only the collagenous part of the C1q molecule was used as the antigen in the ELISA, essentially as described by Må rtensson et al. [10] . For samples taken from September 2011 onwards, whole C1q (Calbiochem, San Diego, CA, USA) was used as antigen [11] . Western blot of separated C1q protein A, B and C chains was performed essentially as described by Må rtensson et al. [10] .
Statistical analyses
Statistical analyses were performed using the Statistical Package for the Social Sciences, SPSS version 22.0 for Windows (IBM SPSS Statistics). Differences between groups were analysed by Student's t test, MannWhitney U test and 2 test, and data were presented as the mean and S.D. or the median and interquartile range (IQR) when appropriate. The numerator for https://academic.oup.com/rheumatology the incidence estimates was the number of patients diagnosed with HUV between 2000 and 2015. The denominator population for the incidence rates is the mean adult population during the study period. For the prevalence estimates, the numerator was all patients with HUV who were alive and living in the study area at the date of point prevalence estimates, that is, 31 December 2015. The denominator was the total adult population on the date of point prevalence estimate. A value of P < 0.05 was considered significant. The KaplanMeier method was used to estimate survival rates. The 95% CI was calculated assuming a Poisson distribution of the observed cases. The study protocol was approved by the Regional Ethics Review Board, Lund, Sweden (2010/668 and 2012/252). Patient consent was not required by the ethical board.
Results
Sixteen patients with HUV (anti-C1q vasculitis), 14 of whom were female (88%), were identified during the study period. Demographics, clinical and laboratory characteristics of patients are detailed in Table 1 . All patients were of Swedish ancestry. The median (IQR) age at diagnosis was 51 (40.756.7) years. Median (IQR) diagnosis delay, that is, time from first symptom attributable to HUV until diagnosis, was 12 (5.019.7) months. The diagnosis was based on pathology reports (any biopsy) in 13 of 16 cases (81%). Fifteen of 16 patients (94%) had reduced levels of classical complement components in plasma, and all patients tested positive for anti-C1q antibodies by ELISA at least once during the study period.
Western blot was performed in 15 of 16 patients, and confirmed positive in 9 of these (60%). Organ involvement, initial therapies, co-morbidities and outcome are summarized in Table 2 . At the time point of diagnosis, the most frequent clinical manifestations were urticaria (n = 16, 100%), followed by arthritis/arthralgia (n = 14, 88%), biopsy-proven glomerulonephritis, episcleritis/scleritis and dyspnoea (n = 3, 19%, each), and recurrent abdominal pain (n = 2, 13%). The cumulative frequency of organ manifestations during follow-up was as follows: urticaria (n = 16, 100%), arthritis/arthralgia (n = 14, 88%) and pulmonary involvement (n = 10, 63%). There were no differences in demographic, clinical or laboratory characteristics at the time of diagnosis between patients with and without positive anti-C1q analyses carried out by western blot (data not shown). The most common initial therapy used was prednisolone (n = 14, 88%), followed by HCQ (n = 9, 56%), MMF (n = 5, 31%) and AZA (n = 3, 19%). The median (IQR) prednisolone dose at diagnosis was 30 (1540) mg/day. Data on
FIG. 1 Study areas
To the right is the map of Sweden. The left map shows study area A (within the county of Skå ne) and study area B (Ö stergö tland county). The distance between areas A and B is 400 km. smoking habits were available for 15 patients; 13 were ever-smokers (4 current smokers and 9 former smokers at diagnosis), and 2 were never-smokers.
Annual incidence rate
The mean annual incidence rate per million inhabitants was estimated to be 0.7 (95% CI: 0.4, 1.1) and was significantly higher among females than males [1.3 (95% CI: 0.6, 1.9) vs 0.2 (95% CI: 0, 0.4), P = 0.003; Table 3 ]. The incidence rate was slightly higher in Ö stergö tland (study area B) than in Skå ne (study area A), 1.3 per million inhabitants (95% CI: 0.5, 2.2) vs 0.5 (95% CI: 0.1, 0.8), P = 0.03. Ten cases were diagnosed in the age group 1554 years and six in the age group 555 years. The age-specific incidence rates were comparable among age groups 1554 and 555 years (P = 0.88; Table 4 ). No cases were diagnosed in the age group 014 years. The incidence rate per year was stable throughout the study period. 
Point prevalence
On the date of point prevalence estimate, 14 cases were alive and living within the study area, resulting in a point prevalence per million inhabitants of 9.5 (95% CI: 4.5, 14.5) for all patients, 16.2 (95% CI: 7, 25.4) for females and 2.7 (95% CI: 0, 6.5) for males (P = 0.007). The prevalence did not differ significantly between the two study areas [study area A: 6.8 (95% CI: 1.8, 11.8) vs 15.7 (95% CI: 4.1, 27.3), P = 0.10; Table 5 ]. The point prevalence in the age group 555 years (57% of cases) was 18. . During follow-up, 8 out of 16 patients were diagnosed with COPD; 6 of whom suffered from both COPD and emphysema. Of the patients with COPD, five were current smokers at time of HUV diagnosis, two were former smokers, and one patient had never smoked. The mean (S.D.) age at diagnosis for patients who developed COPD was 52.2 (7.7) years compared with 46.3 (12.6) years for those without concomitant COPD (P = 0.30). Patients with COPD had longer diagnosis delay than those without COPD (13.5 vs 5.5 months), although these differences were not statistically significant (P = 0.61). Two patients were deceased during the followup period; one 57-year-old female patient died from COPD, septicaemia and ESRD 52 months after diagnosis of HUV, and one 72-year-old female patient died from ESRD 65 months after the HUV diagnosis. The 1-, 5-and 10-year survivals were 100, 92 and 83%, respectively.
Discussion
Although >45 years have passed since HUV (anti-C1q vasculitis) was first described by McDuffie et al. [2] at the Mayo Clinic, the data on epidemiology, disease outcomes, prognosis and clinical features are still limited. To our knowledge, we are presenting the first comprehensive epidemiological data on HUV. Earlier observations, and a more recent study, suggest a rare prevalence of urticarial vasculitis among patients with cutaneous vasculitis, with heart (including pericarditis); IHD: ischemic heart disease; J: joints; K: kidney; L: lungs; M: male; NA: not available, last follow-up for all patients 31 December 2015 or death; PE: plasma exchange; PNS: peripheral nervous system; Pred: prednisolone; S: skin.
very few patients in the study progressing to HUV [12, 13] . Thus, it is hard to compare our results on the epidemiology of HUV directly with mentioned studies because we adhered strictly to the CHCC 2012 definitions of HUV [1] . However, the overall annual incidence rate of 0.7 per million inhabitants is comparable to that of other vasculitides of small and medium-sized vessels, such as polyarteritis nodosa and eosinophilic granulomatosis with polyangiitis [14] . Studying the epidemiology of rare diseases is challenging because it requires a long period of observation and a large population. Furthermore, the availability of consensus criteria or definitions is crucial for performing such studies. The CHCC 2012 defined the HUV syndrome as 'vasculitis accompanied by urticaria and hypocomplementaemia affecting small vessels and accompanied with anti-C1q antibodies' [1] . All the patients in the present study fulfilled the CHCC definitions. Our study also showed a significantly higher incidence of HUV among women, with a female to male ratio of 7:1, comparable to the 8:1 ratio previously reported in a study by Wisnieski et al. [15] . Such a difference in sex specific incidence is not evident in ANCA associated vasculitis [16] , but rather similar to what has been described in epidemiological studies of SLE [17, 18] .
The hitherto largest series of HUV patients was compiled by Jachiet et al. [7] , but did not include estimates of prevalence. They reported two peaks in the age-specific incidence rates (i.e. 4050 and 6070 years), which is in line with our findings. However, the French study also included many cases without detectable anti-C1q antibodies, albeit the vast majority of these patients showed decreased levels of C1q. Which anti-C1q assay was used in their study, and whether or not the same assay was used for all 57 patients, is uncertain. Given that the presence of positive anti-C1q antibodies was a mandatory criterion in the present study, it is unclear how our epidemiological data would have changed if applying the criteria used by Jachiet et al. [7] .
Even though their cohort was almost four times as large as the Swedish one, and despite the mentioned differences in serology, the clinical phenotypes of included patients were similar. The exception was COPD, which had a higher prevalence in the present study compared with that reported by Jachiet et al. [7] .
Although rare, HUV is a potentially life-threatening condition. In this cohort, 50% of our patients were diagnosed with COPD during the disease course. Sixty-one per cent of the patients in a study by Wisnieski et al. [15] suffered from progressive dyspnoea and moderate to severe airway obstruction in pulmonary function testing. Compared with SLE, this is a high figure, as shown in a study from southern Sweden, where 17% of the patients with SLE suffered from COPD [19] . The association between tobacco smoking and COPD is well known, and considering the high prevalence of ever-smokers in the present study, an association between COPD and smoking among the patients in the present study cannot be excluded. However, the prevalence of smoking in our cohort does not fully explain this high figure, because not all smokers developed COPD. Although the number of patients is small, this suggests that there might be other factors related to HUV that predispose to the development of COPD. Two retrieval sources were used to identify potential HUV cases in the present study: medical records and the clinical immunology database in Lund. Given that the clinical characteristics were carefully collected by the authors, including a critical review to ascertain diagnosis, we feel confident that the specificity of HUV diagnosis among the 16 patients is the highest possible. Whether the sensitivity of HUV case retrieval is equally high remains somewhat more uncertain owing to the lack of a specific and widely accepted ICD-code for HUV. Thus, all patients in whom anti-C1q antibodies were analysed and detected during the study period are captured herein. In addition, the access to health care in Sweden is universal, which offers extraordinarily good opportunities to perform epidemiological studies and prevents potential bias with regard to the sensitivity of case retrieval. We have recently used similar methods to identify cases with renal involvement in SLE and ANCA-associated vasculitis [20] .
Worldwide, anti-C1q antibodies are mainly analysed by ELISA-based techniques [21, 22] . The target epitopes of anti-C1q found in HUV are usually different from that of anti-C1q in SLE, and this can be used to differentiate between the two conditions [10] . Anti-C1q antibodies from SLE patients typically are positive only by ELISA and do not bind separated C1q protein chains, whereas the antibodies from HUV patients in the majority of cases bind the C1q B and C protein chains on western blot analysis, in addition to binding the collagenous part of the intact C1q molecule in ELISA [10] . In the present cohort, we found no differences in clinical characteristics between patients with and without positive anti-C1q analyses carried out by western blot.
Our study has limitations. The retrospective design of the study constitutes a potential cause of some missing data. As there is no generally accepted diagnosis code for the HUV, physicians might use different ICD-codes for this disease, which might have affected the complete case findings in our study. By definition, we chose to present data on anti-C1q vasculitis, which with no doubt will affect the comparability of our study with other case series in which anti-C1q seropositivity was not a mandatory criterion.
To conclude, we are presenting here the first epidemiological study of HUV (anti-C1q vasculitis) including data on prevalence, incidence, disease outcomes, prognosis and clinical features from two separate areas of Sweden during a 16-year period. The high coverage of patients, which was enabled by the public and tax-funded Swedish health-care system, constitutes a major strength of the study. The estimation of incidence and prevalence indicates that this condition is rare but not always benign. Renal and lung manifestations were severe in some cases, highlighting the need for careful screening and monitoring of this potentially serious disease.
